{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:21:22Z","timestamp":1762917682145,"version":"3.40.5"},"reference-count":73,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001501","name":"University Grants Commission (UGC)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.ijpharm.2016.05.008","type":"journal-article","created":{"date-parts":[[2016,5,3]],"date-time":"2016-05-03T16:08:56Z","timestamp":1462291736000},"page":"61-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Investigation of imatinib loaded surface decorated biodegradable nanocarriers against glioblastoma cell lines: Intracellular uptake and cytotoxicity studies"],"prefix":"10.1016","volume":"507","author":[{"given":"Abrar M.","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhan Jalees","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amulya K.","family":"Panda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5301-5298","authenticated-orcid":false,"given":"Sushama","family":"Talegaonkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpharm.2016.05.008_bib0005","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1021\/la971117c","article-title":"A record nine different phases (Four cubic, two hexagonal, and one lamellar lyotropic liquid crystalline and two micellar solutions) in a ternary isothermal system of an amphiphilic block copolymer and selective solvents (Water and oil)","volume":"14","author":"Alexandridis","year":"1998","journal-title":"Langmuir"},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0010","doi-asserted-by":"crossref","first-page":"471032","DOI":"10.1155\/2014\/471032","article-title":"Comparison of (99m)tc-tetrofosmin and (99m)tc-sestamibi uptake in glioma cell lines: the role of p-glycoprotein expression","volume":"2014","author":"Alexiou","year":"2014","journal-title":"Int. J. Mol. Imaging"},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0015","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ijpharm.2010.03.034","article-title":"Optimization and physicochemical characterization of a triamcinolone acetonide-loaded NLC for ocular antiangiogenic applications","volume":"393","author":"Araujo","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0020","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.physbeh.2011.05.024","article-title":"Principles of strategic drug delivery to the brain (SDDB): development of anorectic and orexigenic analogs of leptin","volume":"105","author":"Banks","year":"2011","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0025","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jconrel.2008.04.013","article-title":"Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers","volume":"130","author":"Batrakova","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0030","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1054\/bjoc.2001.2165","article-title":"Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: selective energy depletion","volume":"85","author":"Batrakova","year":"2001","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0035","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1023\/A:1019854327540","article-title":"Comparative uptake studies of bioadhesive and non-bioadhesive nanoparticles in human intestinal cell lines and rats: the effect of mucus on particle adsorption and transport","volume":"19","author":"Behrens","year":"2002","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0040","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1158\/1078-0432.CCR-08-1316","article-title":"Local delivery of poly lactic-co-glycolic acid microspheres containing imatinib mesylate inhibits intracranial xenograft glioma growth","volume":"15","author":"Benny","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0045","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1208\/s12249-011-9675-1","article-title":"Brimonidine tartrate-eudragit long-acting nanoparticles: formulation, optimization, in vitro and in vivo evaluation","volume":"12","author":"Bhagav","year":"2011","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0050","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1158\/0008-5472.CAN-04-2416","volume":"65","author":"Breedveld","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0055","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1124\/dmd.111.043083","article-title":"Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice","volume":"40","author":"Bundgaard","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0060","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ijpharm.2009.09.004","article-title":"Comparison of anti-tumor efficacy of paclitaxel delivered in nano- and microparticles","volume":"383","author":"Chakravarthi","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0065","article-title":"Imatinib\u2014an overview","volume":"1(8","author":"Deininger","year":"2009"},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0070","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2147\/IJN.S18905","article-title":"Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents","volume":"6","author":"Dinarvand","year":"2011","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0075","first-page":"555","article-title":"Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells","volume":"38","author":"Dong","year":"2011","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0080","doi-asserted-by":"crossref","first-page":"246","DOI":"10.5607\/en.2014.23.3.246","article-title":"Increasing the efficiency of parkinson's disease treatment using a poly(lactic-co-glycolic acid) (PLGA) based L-DOPA delivery system","volume":"23","author":"Gambaryan","year":"2014","journal-title":"Exp. Neurobiol."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0085","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ijpharm.2010.03.044","article-title":"Deoxycholic acid modified-carboxymethyl curdlan conjugate as a novel carrier of epirubicin: in vitro and in vivo studies","volume":"392","author":"Gao","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0090","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ejpb.2009.09.003","article-title":"Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters","volume":"74","author":"Gelperina","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4172\/2167-7956.1000e113","article-title":"Nanoparticle-based brain targeted delivery systems","volume":"2","author":"Grover","year":"2013","journal-title":"J. Biomol. Res. Ther."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/sj.clpt.6100201","article-title":"Imatinib disposition and ABCB1 (MDR1: P-glycoprotein) genotype","volume":"82","author":"Gurney","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0105","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1038\/sj.onc.1209497","article-title":"Characterization of an imatinib-sensitive subset of high-grade human glioma cultures","volume":"25","author":"Hagerstrand","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0110","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/2193-1801-3-111","article-title":"Response to imatinib as a function of target kinase expression in recurrent glioblastoma","volume":"3","author":"Hassler","year":"2014","journal-title":"SpringerPlus"},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0115","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.bcmd.2004.11.006","article-title":"Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor","volume":"34","author":"Holdhoff","year":"2005","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0120","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11060-009-0008-0","article-title":"Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme","volume":"97","author":"Holdhoff","year":"2010","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0125","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ijpharm.2015.01.002","article-title":"Intravenous delivery of camptothecin-loaded PLGA nanoparticles for the treatment of intracranial glioma","volume":"479","author":"Householder","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0130","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1021\/mp200011f","article-title":"Augmented anticancer efficacy of doxorubicin-loaded polymeric nanoparticles after oral administration in a breast cancer induced animal model","volume":"8","author":"Jain","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0135","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.biomaterials.2010.09.037","article-title":"The effect of the oral administration of polymeric nanoparticles on the efficacy and toxicity of tamoxifen","volume":"32","author":"Jain","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0140","first-page":"18","article-title":"Unraveling the cytotoxic potential of Temozolomide loaded into PLGA nanoparticles. Daru: journal of Faculty of Pharmacy","volume":"22","author":"Jain","year":"2014","journal-title":"Tehran Univ. Med. Sci."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0145","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2217\/nnm.12.86","article-title":"Nanobiotechnology-based strategies for crossing the blood-brain barrier","volume":"7","author":"Jain","year":"2012","journal-title":"Nanomedicine (London, England)"},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0150","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s11095-008-9763-4","article-title":"Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats","volume":"26","author":"Kalaria","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0155","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1593\/tlo.09280","article-title":"Three paths to better tyrosine kinase inhibition behind the blood-brain barrier in treating chronic myelogenous leukemia and glioblastoma with imatinib","volume":"3","author":"Kast","year":"2010","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0160","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.colsurfb.2012.10.056","article-title":"Eudragit RL 100-based nanoparticulate system of aceclofenac for ocular delivery","volume":"103","author":"Katara","year":"2013","journal-title":"Colloids Surf. B"},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0165","first-page":"5143","article-title":"Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class","volume":"60","author":"Kilic","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0170","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.2147\/IJN.S19497","article-title":"Preparation of polylactide-co-glycolide nanoparticles incorporating celecoxib and their antitumor activity against brain tumor cells","volume":"6","author":"Kim","year":"2011","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajps.2013.07.001","article-title":"The endocytosis and intracellular fate of nanomedicines: implication for rational design","volume":"8","author":"Kou","year":"2013","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0180","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ijpharm.2014.12.070","article-title":"Targeting delivery of etoposide to inhibit the growth of human glioblastoma multiforme using lactoferrin- and folic acid-grafted poly(lactide-co-glycolide) nanoparticles","volume":"479","author":"Kuo","year":"2015","journal-title":"Int. J. Pharm"},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0185","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1073\/pnas.0608611104","article-title":"Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus","volume":"104","author":"Lai","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0190","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jconrel.2006.02.014","article-title":"Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition","volume":"112","author":"Lamprecht","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0195","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1021\/ja0436446","article-title":"Hydroxyl stereochemistry and amine number within poly(glycoamidoamine)s affect intracellular DNA delivery","volume":"127","author":"Liu","year":"2005","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0200","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ijpharm.2004.11.027","article-title":"PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution","volume":"290","author":"Mainardes","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0205","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1593\/tlo.12400","article-title":"In vitro and In vivo analysis of RTK inhibitor efficacy and identification of its novel targets in glioblastomas","volume":"6","author":"Martinho","year":"2013","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0210","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3171\/jns.1991.74.3.0460","article-title":"Expression of P-glycoprotein in human glioma cell lines and surgical glioma specimens","volume":"74","author":"Matsumoto","year":"1991","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0215","article-title":"PLGA nanoparticles formed by single- or double-emulsion with vitamin E-TPGS","volume":"51015","author":"McCall","year":"2013","journal-title":"J. Visualized Exp."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0220","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/jbm.a.34040","article-title":"Effects of surfactants on the properties of PLGA nanoparticles","volume":"100","author":"Menon","year":"2012","journal-title":"J. Biomed. Mater. Res. Part A"},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0225","doi-asserted-by":"crossref","first-page":"10655","DOI":"10.1021\/nn504210g","article-title":"Brain-penetrating nanoparticles improve paclitaxel efficacy in malignant glioma following local administration","volume":"8","author":"Nance","year":"2014","journal-title":"ACS nano"},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0230","article-title":"Development of high sensitivity RP-HPLC method & stress testing of imatinib mesylate","author":"Negi","year":"2013","journal-title":"J. Adv. Pharm. Educ. Res."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0235","doi-asserted-by":"crossref","first-page":"015104","DOI":"10.1088\/0957-4484\/24\/1\/015104","article-title":"A logical approach to optimize the nanostructured lipid carrier system of irinotecan: efficient hybrid design methodology","volume":"24","author":"Negi","year":"2013","journal-title":"Nanotechnology"},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0240","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jconrel.2010.08.021","article-title":"Paclitaxel-loaded Pluronic nanoparticles formed by a temperature-induced phase transition for cancer therapy","volume":"148","author":"Oh","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0245","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1602\/neurorx.2.1.108","article-title":"Drug transport to brain with targeted nanoparticles","volume":"2","author":"Olivier","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0250","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bbrc.2014.04.063","article-title":"Gleevec\/imatinib an ABL2 kinase inhibitor, protects tumor and endothelial cells from semaphorin-induced cytoskeleton collapse and loss of cell motility","volume":"448","author":"Procaccia","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0255","first-page":"4575","article-title":"Influence of imatinib mesylate on radiosensitivity of astrocytoma cells","volume":"29","author":"Ranza","year":"2009","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0260","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s11060-009-9975-4","article-title":"In-vitro effects of the tyrosine kinase inhibitor imatinib on glioblastoma cell proliferation","volume":"96","author":"Ranza","year":"2010","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0265","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0927-7765(99)00063-6","article-title":"Stabilization and activation of Pluronic micelles for tumor-targeted drug delivery","volume":"16","author":"Rapoport","year":"1999","journal-title":"Colloids Surf. B"},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0270","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1038\/sj.bjc.6605411","article-title":"Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma","volume":"101","author":"Reardon","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0275","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1002\/cncr.24213","article-title":"Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma","volume":"115","author":"Reardon","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0280","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1742-7843.2008.00371.x","article-title":"Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells","volume":"104","author":"Ren","year":"2009","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0285","doi-asserted-by":"crossref","first-page":"517","DOI":"10.7314\/APJCP.2014.15.2.517","article-title":"PLGA-based nanoparticles as cancer drug delivery systems","volume":"15","author":"Sadat Tabatabaei Mirakabad","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0290","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/jcp.20659","article-title":"Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation","volume":"208","author":"Servidei","year":"2006","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0295","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1080\/10611860903046628","article-title":"Paclitaxel-loaded PLGA nanoparticles surface modified with transferrin and Pluronic((R))P85, an in vitro cell line and in vivo biodistribution studies on rat model","volume":"17","author":"Shah","year":"2009","journal-title":"J. Drug Target"},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0300","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/ijc.24030","article-title":"Inhibition of autophagy at a late stage enhances imatinib-induced cytotoxicity in human malignant glioma cells","volume":"124","author":"Shingu","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0305","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3109\/03602532.2013.864664","article-title":"The effect of nanoparticle properties detection method, delivery route and animal model on poly(lactic-co-glycolic) acid nanoparticles biodistribution in mice and rats","volume":"46","author":"Simon","year":"2014","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0310","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ijpharm.2007.08.034","article-title":"PLGA nanoparticles simultaneously loaded with vincristine sulfate and verapamil hydrochloride: systematic study of particle size and drug entrapment efficiency","volume":"350","author":"Song","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0315","unstructured":"Sooman, L., 2014. Prognostic Biomarkers and Target Proteins for Treatment of High-grade Gliomas."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0320","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/sj.jcbfm.9600414","article-title":"Novel delivery system enhances efficacy of antiretroviral therapy in animal model for HIV-1 encephalitis","volume":"27","author":"Spitzenberger","year":"2007","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0325","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.colsurfb.2015.02.043","article-title":"Biodegradable polymeric nanoparticles for oral delivery of epirubicin: in vitro, ex vivo, and in vivo investigations","volume":"128","author":"Tariq","year":"2015","journal-title":"Colloids Surf. B"},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0330","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ejps.2010.06.008","article-title":"Enhanced efficacy of functionalized epirubicin liposomes in treating brain glioma-bearing rats","volume":"41","author":"Tian","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0335","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jcis.2012.11.062","article-title":"Magnetic nanoparticles (MNPs) covalently coated by PEO-PPO-PEO block copolymer for drug delivery","volume":"395","author":"Wang","year":"2013","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0340","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.colsurfb.2014.07.004","article-title":"Dorzolamide-loaded PLGA\/vitamin E TPGS nanoparticles for glaucoma therapy: pharmacoscintigraphy study and evaluation of extended ocular hypotensive effect in rabbits","volume":"122","author":"Warsi","year":"2014","journal-title":"Colloids Surf. B"},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0345","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s11095-007-9347-8","article-title":"Natural and synthetic polymers as inhibitors of drug efflux pumps","volume":"25","author":"Werle","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0350","first-page":"1089","article-title":"Effect of imatinib at different concentrations on rat C6 glioma cell apoptosis and cell cycle","volume":"30","author":"Yang","year":"2010","journal-title":"Nan Fang Yi Ke Da Xue Bao"},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0355","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1021\/mp300649z","article-title":"Improved transport and absorption through gastrointestinal tract by PEGylated solid lipid nanoparticles","volume":"10","author":"Yuan","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0360","doi-asserted-by":"crossref","first-page":"13340","DOI":"10.3390\/molecules181113340","article-title":"Preparation and optimization of triptolide-loaded solid lipid nanoparticles for oral delivery with reduced gastric irritation","volume":"18","author":"Zhang","year":"2013","journal-title":"Molecules (Basel Switzerland)"},{"key":"10.1016\/j.ijpharm.2016.05.008_bib0365","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijpharm.2006.09.060","article-title":"Quality by design: understanding the formulation variables of a cyclosporine A self-nanoemulsified drug delivery systems by Box-Behnken design and desirability function","volume":"332","author":"Zidan","year":"2007","journal-title":"Int. J. Pharm."}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037851731630374X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037851731630374X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T22:41:21Z","timestamp":1572561681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S037851731630374X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":73,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S037851731630374X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2016.05.008","relation":{},"ISSN":["0378-5173"],"issn-type":[{"type":"print","value":"0378-5173"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigation of imatinib loaded surface decorated biodegradable nanocarriers against glioblastoma cell lines: Intracellular uptake and cytotoxicity studies","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpharm.2016.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}